PIRS Pieris Pharmaceuticals Inc Gross Profit Rate

Corporate emblem and logo of Pieris (PIRS)

The gross margin as a percentage of revenue demonstrates efficiency dynamics, where the value 0.00 reflects the metric's balance for Pieris Pharmaceuticals (PIRS). The business model relies on protein licensing to minimize production costs. However, liquidity shortages and capital burn complicate development. Stability is provided by the Anticalin platform developments and partnerships with industry behemoths in the US and Germany to combat oncology.

PIRS Pieris Pharmaceuticals, Inc. Gross Profitability (07/04/2022 - 11/20/2026)

Analytical breakdowns and data insights for company Pieris (PIRS)

- stock value and consensus price forecast:
Manufactured products of Pieris Pharmaceuticals Inc

Gross margin determines the portion of revenue remaining after covering direct production costs, serving as a fundamental indicator of operational efficiency. Analyzing this metric through gross profit margin trends allows for an assessment of the business's ability to generate profit before accounting for administrative expenses. For Pieris Pharmaceuticals (PIRS), this figure reflects the commercial value of anti-kalin development within asthma and oncology therapy partnerships.

Direct competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin ENTX (Entera Bio)|Gross Sales Margin MindWalk Therapeutics|ABVC: Return on Gross Profit|CPIX - Gross Margin|QNTM (Quantum BioPharma) - Return on Gross Profit|Gross Profitability Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Gross Margin|Gross Margin ranitherapeutics.com|Gross Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Gross Return on Sales|lexariabioscience.com - Return on Gross Profit|Gross Margin Pulmatrix Inc PULM|Pheton Holdings - Gross Margin|Gross Profitability Margin APM|Lyra Therapeutics, Inc. (LYRA) - Gross Profitability|Gross Profit Margin Impact BioMedical, Inc. (IBO)|Gross Profitability TNF Pharma|YCBD: Gross Profit Rate|Gross Margin PRFX|CYTO - Gross Profit Margin|Gross Profitability Lipella LIPO|Gross Profit Ratio OPTN (OptiNose, Inc.)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin